Shanghai exchange rebukes BrightGene for statements on remdesivir

BrightGene shares tumbled as the Shanghai exchange reprimanded the company for misstatements regarding its production of antiviral candidate remdesivir from Gilead.

In a statement Sunday, the exchange reported the results of its investigation into a Feb. 12 filing from BrightGene

Read the full 392 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE